AXL and non-small cell lung carcinoma: As AXL has been reported to drive acquired resistance to TKIs in NSCLC we evaluated its protein expression, as well as expression of the EMT marker vimentin to determine if an EMT phenotype could explain the resistance observed in the CUTO33 cell line.5, 10, 18